- Home
- PFLT vs REPL Comparison
PFLT vs REPL Comparison
Compare PFLT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- REPL
- Stock Information
- Founded
- PFLT 2010
- REPL 2015
- Country
- PFLT United States
- REPL United States
- Employees
- PFLT N/A
- REPL N/A
- Industry
- PFLT Finance: Consumer Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PFLT Finance
- REPL Health Care
- Exchange
- PFLT Nasdaq
- REPL Nasdaq
- Market Cap
- PFLT 885.6M
- REPL 780.3M
- IPO Year
- PFLT N/A
- REPL 2018
- Fundamental
- Price
- PFLT $11.30
- REPL $11.85
- Analyst Decision
- PFLT Strong Buy
- REPL Strong Buy
- Analyst Count
- PFLT 2
- REPL 6
- Target Price
- PFLT $12.00
- REPL $17.50
- AVG Volume (30 Days)
- PFLT 871.5K
- REPL 818.5K
- Earning Date
- PFLT 02-10-2025
- REPL 02-06-2025
- Dividend Yield
- PFLT 10.88%
- REPL N/A
- EPS Growth
- PFLT 80.92
- REPL N/A
- EPS
- PFLT 1.40
- REPL N/A
- Revenue
- PFLT $186,355,000.00
- REPL N/A
- Revenue This Year
- PFLT $23.81
- REPL N/A
- Revenue Next Year
- PFLT N/A
- REPL $300.41
- P/E Ratio
- PFLT $8.09
- REPL N/A
- Revenue Growth
- PFLT 33.74
- REPL N/A
- 52 Week Low
- PFLT $10.28
- REPL $4.92
- 52 Week High
- PFLT $12.02
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- PFLT 66.05
- REPL 51.79
- Support Level
- PFLT $10.81
- REPL $10.05
- Resistance Level
- PFLT $11.09
- REPL $11.20
- Average True Range (ATR)
- PFLT 0.12
- REPL 0.92
- MACD
- PFLT 0.04
- REPL -0.08
- Stochastic Oscillator
- PFLT 96.83
- REPL 51.97
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.